While IDH1/2 mutations most commonly occur in Grade II and III gliomas, they are also present in approximately 5% of GBM that have progressed from lower grade gliomas, known as secondary GBM [3, 7]. This evidence concerns the gene IDH1 and central nervous system cancer.